By Josh Beckerman
Shares of Enveric Biosciences shares fell after the company reported a $5 million public offering.
The stock was down 44%, to $2.17, Friday afternoon and are down about 83% over the past 52 weeks.
Shares ended the regular session Thursday at $3.90, and peaked at $6.48 in after-hours trading, according to Nasdaq.com, after the company said it received a Notice of Allowance from the U.S. Patent and Trademark Office.
The patent application pertained to EVM301 molecules being developed as potential treatments for mental-health disorders.
Later Thursday night, the company said a public offering of an aggregate of 1.67 shares, or stock equivalents in lieu thereof, 1.67 million Series A warrants and 1.67 million Series B warrants priced at a combined price of $3 per share or stock equivalent and accompanying warrants.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 31, 2025 13:51 ET (18:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.